01541nam 2200421Ia 450 991069897850332120090618110942.0(CKB)5470000002398088(OCoLC)402487747(EXLCZ)99547000000239808820090618d2005 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticalsRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :Center for Biologics Evaluation and Research,[2005]10 pages digital, PDF fileTitle from PDF title page (viewed on June 19th, 2009)."ICH"."October 2005".Guidance for industry HeartVentriclesPalpitationDrugsTestingHeartVentricles.Palpitation.DrugsTesting.Center for Drug Evaluation and Research (U.S.)Center for Biologics Evaluation and Research (U.S.)International Conference on Harmonisation.GPOGPOBOOK9910698978503321Guidance for industry3434577UNINA